Immunotherapy has reshaped the therapeutic landscape: blockade of the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis has produced clinically meaningful activity in unresectable HCC and is being explored in the neoadjuvant setting (13). Here, PDCD1 is linked to hepatocellular carcinoma.